These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8620338)

  • 1. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism.
    Gaw A; Packard CJ; Lindsay GM; Murray EF; Griffin BA; Caslake MJ; Colquhoun I; Wheatley DJ; Lorimer AR; Shepherd J
    Arterioscler Thromb Vasc Biol; 1996 Feb; 16(2):236-49. PubMed ID: 8620338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of simvastatin on the number and composition of apoproteinB-containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method.
    Ikeda Ryomoto K; Suzuki M; Tsushima M; Yamamoto A; Harano Y
    Endocr J; 1996 Oct; 43(5):469-75. PubMed ID: 8980885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol.
    Simons LA; Simons J; Parfitt A
    Med J Aust; 1992 Oct; 157(7):455-9. PubMed ID: 1406395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of simvastatin on apoB metabolism and LDL subfraction distribution.
    Gaw A; Packard CJ; Murray EF; Lindsay GM; Griffin BA; Caslake MJ; Vallance BD; Lorimer AR; Shepherd J
    Arterioscler Thromb; 1993 Feb; 13(2):170-89. PubMed ID: 8427854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
    Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
    Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.
    Sweany AE; Shapiro DR; Tate AC; Goldberg RB; Stein EA
    Clin Ther; 1995; 17(2):186-203. PubMed ID: 7614520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of apolipoprotein B in primary moderate hypercholesterolaemia: effects of acipimox and cholestyramine therapy.
    Gaw A; Packard CJ; Lindsay GM; Collins SM; Lorimer AR; Shepherd J
    Eur J Med Res; 1995 Oct; 1(1):38-48. PubMed ID: 9392692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
    Schrott HG; Stein EA; Dujovne CA; Davidson MH; Goris GB; Oliphant TH; Phillips JC; Shawaryn GG
    Am J Cardiol; 1995 Jan; 75(1):34-9. PubMed ID: 7801861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
    Arad Y; Ramakrishnan R; Ginsberg HN
    J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol.
    Desager JP; Horsmans Y; Harvengt C
    J Clin Pharmacol; 1991 Jun; 31(6):537-42. PubMed ID: 1880219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
    Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
    Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
    Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
    Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.